• Respiratory and thoracic cancers

Tabrecta Generic Name & Formulations

General Description

Capmatinib 150mg, 200mg; tabs.

Pharmacological Class

Kinase inhibitor.

How Supplied


Generic Availability


Mechanism of Action

Capmatinib inhibits MET, including the mutant variant produced by exon 14 skipping. This results in a protein with a missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling.

Tabrecta Indications


In adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.

Tabrecta Dosage and Administration


Confirm presence of a mutation that leads to MET exon 14 skipping in tumor specimens. Swallow whole. 400mg twice daily. Dose modifications for adverse reactions: see full labeling.


Not established.

Tabrecta Contraindications

Not Applicable

Tabrecta Boxed Warnings

Not Applicable

Tabrecta Warnings/Precautions


Monitor for pulmonary symptoms indicative of ILD/pneumonitis; withhold immediately if suspected and permanently discontinue if no other causes are identified. Monitor LFTs prior to initiation, every 2 weeks during 1st 3 months, then once monthly or as clinically indicated; test more frequently if increased AST, ALT or bilirubin develops. Monitor amylase and lipase at baseline, and regularly during treatment. Potential risk of photosensitivity. Advise patients to limit direct UV exposure. Severe renal impairment (CrCl 15–29mL/min). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Tabrecta Pharmacokinetics


After oral administration of Tabrecta 400 mg (cancer patients), capmatinib peak plasma concentrations (Cmax) were reached in ~1 to 2 hours (Tmax). The absorption after oral administration is estimated to be >70%.


Plasma protein bound: 96%.

Apparent mean volume of distribution at steady-state: 164 L. 


Primarily CYP3A4  and aldehyde oxidase.


Half-life: 6.5 hours. Mean (%CV) steady-state apparent clearance: 24 L/hr (82%). 

Fecal (78%), renal (22%).

Tabrecta Interactions


Potentiated by strong CYP3A inhibitors; monitor closely. Potentiates CYP1A2, P-gp, or BCRP substrates; if unavoidable, reduce substrate dosage. May potentiate MATE1 or MATE2K substrates; if unavoidable, reduce substrate dosage. Antagonized by strong or possibly moderate CYP3A inducers; avoid.

Tabrecta Adverse Reactions

Adverse Reactions

Peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite, constipation, diarrhea, cough; lab abnormalities, ILD/pneumonitis, hepatotoxicity, pancreatic toxicity, hypersensitivity reactions.

Tabrecta Clinical Trials

See Literature

Tabrecta Note

Not Applicable

Tabrecta Patient Counseling

See Literature